Pardes Biosciences Inc
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About PRDS
Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. Its lead product candidate, pomotrelvir, which targets the coronavirus disease (COVID-19). Pomotrelvir is in clinical development to treat COVID-19 in adult and pediatric patients. The Company, by leveraging its knowledge of structure-based drug design, reversible covalent chemistry and viral biology, it has discovered and is developing novel product candidates with low nanomolar potency against SARS-CoV-2 and activity against all known pathogenic human coronaviruses. Its lead product candidate, pomotrelvir, inhibits the main coronaviral cysteine protease (Mpro), a viral protein essential for replication of all known coronaviruses, including SARS-CoV-2. Inhibiting Mpro prevents the liberation and assembly of the viral replication complex, blocking replication before it begins.
Find out what a historical investment in Pardes Biosciences Inc would be worth today using our PRDS stock calculator.
-
-
-
-
-
-
-
-
-
Ready to start your investing journey with Stake?
Open an accountPRDS FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in PRDS
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in PRDS
on Stake
Buy PRDS from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of PRDS from only US$10 with fractional shares
